Analyst Ratings For Integra Lifesciences (NASDAQ:IART)

.

Some recent analyst ratings include

• 1/9/2018-Barclays Reiterated Rating of Hold.
• 1/5/2018-Cantor Fitzgerald Reiterated Rating of Neutral .
• 1/2/2018-Raymond James Financial Reiterated Rating of Outperform .
• 1/2/2018-Bank of America was Downgraded by analysts at Bank of America from a “Buy ” rating to a ” Neutral” rating.
• 11/9/2017-Royal Bank of Canada Reiterated Rating of Sector Perform .

Recent Insider Trading Activity For Integra Lifesciences (NASDAQ:IART)
Integra Lifesciences (NASDAQ:IART) has insider ownership of 21.50% and institutional ownership of 86.39%.

• On 2/26/2018 Keith Bradley, Director, sold 15,658 with an average share price of $55.00 per share and the total transaction amounting to $861,190.00.
• On 11/20/2017 Jeffrey Mosebrook, Insider, sold 160 with an average share price of $47.41 per share and the total transaction amounting to $7,585.60.
• On 11/14/2017 Richard D Gorelick, VP, sold 1,500 with an average share price of $47.19 per share and the total transaction amounting to $70,785.00.
• On 10/31/2017 Barbara B Hill, Director, bought 10,768 with an average share price of $46.66 per share and the total transaction amounting to $502,434.88.
• On 8/4/2017 Donald E Morel Jr, Director, bought 10,000 with an average share price of $49.25 per share and the total transaction amounting to $492,500.00.
• On 8/3/2017 Donald E Morel Jr, Director, bought 2,500 with an average share price of $49.29 per share and the total transaction amounting to $123,225.00.
• On 8/1/2017 Barbara B Hill, Director, bought 5,050 with an average share price of $49.33 per share and the total transaction amounting to $249,116.50.

Recent Trading Activity for Integra Lifesciences (NASDAQ:IART)
Shares of Integra Lifesciences closed the previous trading session at 53.21 down -0.47 0.88% with shares trading hands.